David S. Hong, MD

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated data with larotrectinib (Vitrakvi) in&nbsp;

fusion-positive solid tumors at the ESMO Congress 2019.&nbsp;

The tumor-agnostic TRK inhibitor larotrectinib showed sustained antitumor activity in adult and pediatric patients with

fusionpositive cancers, based on updated findings from an integrated analysis of an adult phase I trial, the phase I/II SCOUT pediatric trial, and the phase II adult/adolescent NAVIGATE basket trial.

Videos

David S. Hong, MD, discusses&nbsp;updated data with larotrectinib (Vitrakvi) in&nbsp;<em>TRK</em>&nbsp;fusion-positive solid tumors at the ESMO Congress 2019.&nbsp;

Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics and associate vice president of clinical research at The University of Texas MD Anderson Cancer Center, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib (Vitrakvi).

Overall, a significant amount of patients respond to larotrectinib and the responses appear very durable, Hong says. The hope with LOXO-195, another TRK inhibitor, is to see more of these significant responses and durability in these patients. Like many other small molecule agents, the next steps include determining the mechanisms of resistance and if other drugs can be developed that are less toxic.

David S. Hong, MD, discusses the potential for other TRK inhibitors in the treatment landscape for patients with thyroid cancer after the approval of larotrectinib.

Highlighting Promising TRK Inhibitors for the Treatment of Thyroid Cancer

David S. Hong, MD, deputy director of the department of investigational cancer therapeutics and associate vice president at The University of Texas MD Anderson Cancer Center, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic  or recurrent cervical cancer.

The phase I study led to a recommended phase II dose of 2 mg/kg every 3 weeks, according to Hong. This dose showed activity across a number of histologies, but in particular, showed promising results in this patient population with cervical cancer.

<p>David S. Hong, MD, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic&nbsp; or recurrent cervical cancer.</p>


David S. Hong, MD | Authors

Articles

Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors

Highlighting Promising TRK Inhibitors for the Treatment of Thyroid Cancer

Results for Tisotumab Vedotin in Patients With Metastatic or Recurrent Cervical Cancer